Company logo

MSB - Mesoblast Limited

ASX -> Healthcare -> Biotechnology
Melbourne, Australia
Type: Equity

MSB price evolution
MSB
(in millions $) 1 Dec 2024 31 Aug 2024 30 May 2024 2 Mar 2024
Current assets
Cash $62.96 $62.96
Short term investments
Net receivables $4.55 $4.32 $3.39 $2.41
Inventory
Total current assets $100.67 $26.25 $25.13 $26.69
Long term investments $1.01 $1.01
Property, plant & equipment $3.84 $3.84
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $100.67 $26.25 $25.13 $26.69
Current liabilities
Accounts payable $7.07 $7.07
Deferred revenue
Short long term debt $16.49 $16.49
Total current liabilities $5.34 $4.13 $4.48 $5.72
Long term debt $102.44 $102.44
Total noncurrent liabilities
Total debt
Total liabilities $5.34 $4.13 $4.48 $5.72
Shareholders' equity
Retained earnings $95.33 $22.12 $20.65 $20.98
Other shareholder equity $78.3 $78.3
Total shareholder equity $480.36 $480.36
(in millions $) 30 Jun 2024 30 Jun 2023 30 Jun 2022 30 Jun 2021
Current assets
Cash $62.96 $71.32 $60.45 $136.38
Short term investments
Net receivables $20.48 $6.53 $4.4 $4.84
Inventory
Total current assets $86.46 $81.66 $69.84 $148.23
Long term investments $1.01 $1.76 $1.76 $2.08
Property, plant & equipment $3.84 $6.49 $9.96 $12.14
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $669.15 $669.42 $662.14 $744.72
Current liabilities
Accounts payable $7.07 $20.14 $23.08 $19.6
Deferred revenue
Short long term debt $16.49 $10.01 $8.2 $55.97
Total current liabilities $73.24 $41.98 $51.37 $94.27
Long term debt $102.44 $106.48 $98.7 $49.53
Total noncurrent liabilities
Total debt
Total liabilities $188.8 $167.58 $165.1 $163.32
Shareholders' equity
Retained earnings -$908.76 -$820.8 -$738.92 -$541.75
Other shareholder equity $78.3 $73.52 $70.65 -$39.79
Total shareholder equity $480.36 $501.84 $497.04 $581.4
(in millions $) 1 Dec 2024 31 Aug 2024 30 May 2024 2 Mar 2024
Revenue
Total revenue $79 $6.49 $6.25 $6.23
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $0.68 $1.09 $2.77 $1.54
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense
Net income
Net income $78.33 $5.4 $3.48 $4.69
Income (for common shares)
(in millions $) 30 Jun 2023 30 Jun 2022 30 Jun 2021 30 Jun 2020
Revenue
Total revenue $7.5 $10.21 $7.46 $32.16
Cost of revenue $54.92 $63.57 $32.72 $25.31
Gross Profit -$47.42 -$53.36 -$25.26 $6.85
Operating activities
Research & development $27.19 $32.82 $51.54 $54.73
Selling, general & administrative $25.37 $27.21 $30.87 $25.61
Total operating expenses $76.79 $90.78 $92.62 $105.04
Operating income -$69.29 -$80.57 -$85.16 -$72.89
Income from continuing operations
EBIT
Income tax expense -$0.21 -$0.24 -$0.82 -$9.41
Interest expense -$19.44 -$16.91
Net income
Net income -$81.89 -$91.35 -$98.81 -$77.94
Income (for common shares) -$81.89 -$91.35 -$98.81 -$77.94
(in millions $) 1 Dec 2024 31 Aug 2024 30 May 2024 2 Mar 2024
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid -$12.6 -$8.66 -$4.85 -$4.59
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$12.6 -$8.66 -$4.85 -$4.59
Effect of exchange rate
Change in cash and equivalents $71.93 -$2.35 -$2.35 $10.01
(in millions $) 30 Jun 2024 30 Jun 2023 30 Jun 2022 3 Mar 2022
Net income -$87.96 -$81.89 -$91.35
Operating activities
Depreciation $3.18 $2.61
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$48.46 -$63.27 -$65.78
Investing activities
Capital expenditures -$0.27 -$0.26 -$0.16
Investments
Total cash flows from investing -$0.1 -$0.19 -$0.23 $9.91
Financing activities
Dividends paid -$37.52
Sale and purchase of stock $65.41 $88.64 $0.21
Net borrowings -$13.52 -$2.66 -$6.33
Total cash flows from financing $40.25 $74.5 -$9.87 -$37.52
Effect of exchange rate -$0.08 -$0.16
Change in cash and equivalents -$8.36 $10.87 -$76.43 $35.23
Fundamentals
Market cap $31.95M
Enterprise value N/A
Shares outstanding 13.12M
Revenue $97.97M
EBITDA N/A
EBIT N/A
Net Income $91.90M
Revenue Q/Q 1.51K%
Revenue Y/Y 301.91%
P/E ratio 0.35
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 0.33
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS $7.00
ROA 205.66%
ROE N/A
Debt/Equity 0.39
Net debt/EBITDA N/A
Current ratio 18.84
Quick ratio N/A